Central diabetes insipidus is a condition characterized by arginine vasopressin deficiency (AVP, also called antidiuretic hormone, ADH) due to loss, dysfunction, or interruption of the anatomical and functional continuity of hypothalamic magnocellular neurons and their projections to the posterior pituitary. The primary pathophysiological consequence is the inability to appropriately increase urinary concentration in response to osmolarity- and volume-dependent stimuli, with the onset of hypotonic polyuria and polydipsia as cardinal manifestations, sustained by water diuresis that is not adequately restrained by the antidiuretic system.
Unlike diabetes mellitus, in which polyuria is related to osmotic diuresis due to glycosuria, in central diabetes insipidus the loss of free water is primarily determined by the absence or insufficiency of the AVP signal mediated at the level of the collecting duct. In many patients, thirst is initially able to compensate for water loss and maintain plasma sodium and osmolality within range, but the disease becomes clinically dangerous when access to water is limited, thirst perception is reduced, or acute conditions coexist that increase losses or reduce intake.
From a nosological perspective, recent literature tends to consider central diabetes insipidus as part of the spectrum of vasopressin deficiency (arginine vasopressin deficiency), emphasizing that the syndrome is defined more by the loss of the antidiuretic signal than by the clinical phenotype of polyuria alone.
Central diabetes insipidus is considered a relatively rare disorder in the general population, but its frequency increases significantly in selected settings, especially in neurosurgical practice and in the care pathways of hypothalamic-pituitary disorders. In clinical practice, its true prevalence is probably underestimated, since partial forms may present with less evident polyuria, compensated by polydipsia, and remain unrecognized until an acute stressor, hospitalization, or voluntary or iatrogenic restriction of fluid intake exposes free water loss and the tendency toward hypernatremia.
From an etiological perspective, a substantial proportion of cases is secondary to acquired causes, predominantly conditions that produce direct or indirect damage to the supraoptic and paraventricular nuclei, the pituitary stalk, or the posterior pituitary. In this sense, the most typical setting is postoperative disease after pituitary surgery or surgery for suprasellar lesions, in which diabetes insipidus may be transient or permanent and may occur within biphasic or triphasic patterns of altered water and sodium regulation.
Structural and clinical risk factors include tumors of the hypothalamic-pituitary and suprasellar region, such as craniopharyngiomas, germinomas, invasive pituitary adenomas, meningiomas, and metastases, as well as infiltrative and granulomatous diseases. In children and young adults, the presence of central diabetes insipidus associated with pituitary stalk thickening is a warning sign for specific etiological diagnoses, particularly Langerhans cell histiocytosis and germ cell tumors, which require close radiological and clinical follow-up even when onset appears isolated.
Inflammatory and autoimmune settings are also relevant, including lymphocytic infundibulo-neurohypophysitis and IgG4-related forms, as well as sarcoidosis and tuberculosis. In these conditions, the diagnosis of central diabetes insipidus may precede other systemic signs and requires a global assessment integrating clinical findings, imaging, laboratory tests, and, when necessary, targeted biopsy or second-level investigations. Head trauma and subarachnoid hemorrhage are no less important, since they may cause axial or ischemic damage to vasopressinergic circuits with outcomes that vary over time.
Finally, some cases are sustained by genetic forms of neurohypophyseal diabetes insipidus, typically with onset in childhood, related to alterations of the preprovasopressin gene or to other syndromic defects involving the hypothalamic-pituitary axis. In these conditions, risk is amplified by family history, early onset, and progression, with the possible later appearance of additional pituitary deficiencies or neurological comorbidities depending on the etiology.
The pathophysiology of central diabetes insipidus arises from loss of the normal free water control system mediated by AVP. Under physiological conditions, plasma osmolality is detected by highly sensitive hypothalamic osmoreceptors, while changes in effective circulating volume and arterial pressure are integrated by cardiopulmonary and arterial baroreceptors through afferent pathways that modulate vasopressin secretion. Magnocellular neurons of the supraoptic and paraventricular nuclei synthesize AVP as part of a precursor (preprovasopressin), transport it along axons in the pituitary stalk, and release it from the posterior pituitary in response to stimuli, generating an endocrine signal proportional to the need to conserve water.
At renal level, AVP acts predominantly on V2 receptors of the principal cells of the collecting duct. Activation of the V2 receptor, through increased cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA), determines phosphorylation and translocation of aquaporin-2 to the apical membrane, dramatically increasing water permeability and allowing passive reabsorption along the medullary osmotic gradient. This mechanism also depends on the integrity of medullary concentration, supported by solute transport in the loop of Henle and urea recycling, so concomitant disorders that reduce the gradient may attenuate concentrating capacity even if the vasopressin axis is partially restored.
In central diabetes insipidus, AVP secretion is reduced or absent because of causes that may affect synthesis, axonal transport, posterior pituitary release, or the anatomical integrity of the hypothalamic-neurohypophyseal pathway. Acquired forms often result from destruction or disconnection: tumors and infiltrative processes may compress or invade the stalk, surgery may injure fibers and microvasculature, trauma may induce stretching and axonal damage, and autoimmunity may cause inflammation and progressive neuronal loss. Genetic forms, instead, may determine misfolding of the vasopressin precursor with endoplasmic reticulum stress and gradual neuronal degeneration, explaining progressive onset and worsening over time in some children and adolescents.
The immediate consequence of AVP deficiency is the production of large volumes of poorly concentrated urine. Free water loss tends to increase plasma osmolality and sodium, stimulating the thirst center and, when this circuit is intact, triggering behavioral compensation that can maintain balance. The clinical picture becomes more severe when thirst is impaired or cannot be satisfied, as in patients with extensive hypothalamic abnormalities, sedated patients, postoperative patients, subjects with reduced consciousness, or situations in which access to water is limited. In these conditions, central diabetes insipidus presents as an acute water deficit with hypernatremia, hyperosmolality, and neurological risk.
A distinctive aspect is the coexistence of hypothalamic damage involving both the vasopressin system and thirst regulation, giving rise to the adipsic phenotype. In this situation, free water loss is not compensated by voluntary intake, making much stricter therapeutic and monitoring strategies necessary. In addition, in postoperative settings a dynamic sequence may occur: an initial phase of diabetes insipidus due to reduced AVP release, followed by a phase of excessive unregulated release with syndrome of inappropriate antidiuretic hormone secretion (SIADH), and finally a possible late phase of permanent diabetes insipidus when neuronal reserves are exhausted.
The clinical presentation of central diabetes insipidus is dominated by polyuria and polydipsia, but the way these symptoms emerge depends on the rapidity of onset, the completeness of AVP deficiency, and the possibility of access to water. On history taking, the patient typically reports a marked increase in urinary volume with clear urine, the need to drink frequently, and a preference for cold water. Nocturia is a highly suggestive feature, since it disrupts sleep and often becomes the practical reason prompting medical evaluation.
In acute-onset forms, such as after neurosurgery or trauma, polyuria may appear within a few hours, with a rapid increase in diuresis and thirst. In these settings, the patient may report intense thirst, if conscious, or show indirect signs of dehydration if unable to drink. In hospital wards, the onset of high diuresis with rising plasma sodium or osmolality is a crucial warning sign, since progression can be rapid and associated with neurological deterioration.
In chronic and partial forms, symptoms may be more subtle. The patient may adapt by progressively increasing fluid intake, sometimes normalizing plasma sodium, and the disease emerges when intake is reduced, for example during travel, diagnostic procedures, gastrointestinal illness, or periods of voluntary fluid restriction. In these situations, headache, asthenia, irritability, cramps, reduced cognitive performance, and signs of dehydration may occur.
On physical examination, in compensated conditions the patient may appear normally hydrated, making it essential to integrate the assessment with data on diuresis, body weight, and laboratory findings. In decompensated conditions, dry mucous membranes, reduced skin turgor, tachycardia, orthostatic hypotension, and acute weight loss may be observed. When hypernatremia is significant, neurological abnormalities, agitation, lethargy, confusion, and, in the most severe cases, seizures or coma may occur, especially if the rise in natremia is rapid.
In some forms associated with hypothalamic lesions, reduced or absent thirst may be present in addition to polyuria, with a high risk of hyperosmolar dehydration. In these patients, symptoms may be less specific and more related to the consequences of hypernatremia, making diagnosis more difficult unless systematic measurements of diuresis and sodium are performed. Furthermore, in the presence of complex hypothalamic-pituitary disorders, signs of deficiency in other pituitary axes may coexist, such as marked asthenia, hypotension, hypoglycemia, or hypothyroid symptoms, which may mask or complicate the interpretation of the polyuric syndrome.
Suspicion of central diabetes insipidus arises from recognition of a consistent pattern of hypotonic polyuria and intense thirst, in the absence of more common explanations such as hyperglycemia with osmotic diuresis, diuretic therapy, or hypercalcemia. It is essential to reason in terms of the quantity of urine produced and not only urinary frequency, since urinary frequency with small volumes does not point toward a polyuric syndrome. In practice, 24-hour urine collection or controlled measurement of diuresis and urinary osmolality allows early distinction between true polyuria and functional urinary symptoms.
Suspicion becomes particularly strong when diuresis is high and urine is persistently dilute, especially if associated with high-normal or elevated plasma sodium. In a subject with free access to water, sodium may remain within range, but the presence of significant thirst and nocturia suggests that the body is compensating for an antidiuretic defect. Conversely, in settings of limited access to fluids, even a partial form may rapidly progress toward hypernatremia, making timely recognition decisive to prevent neurological complications.
In hospital settings, suspicion must remain very high after pituitary and suprasellar surgery, in patients with head trauma, and after neurovascular events involving hypothalamic structures. In these contexts, diagnosis must not wait for reported symptoms, since the level of consciousness or sedation may prevent reporting of thirst. Increased diuresis, reduced urinary osmolality, and the tendency toward rising sodium represent early signals requiring a structured approach.
Another situation in which the disorder should be suspected is the presence of diabetes insipidus in association with neurological signs, headache, visual disturbances, visual field abnormalities, or anterior pituitary symptoms, which may indicate a sellar or suprasellar lesion. In children and young people, suspicion must include infiltrative and neoplastic causes even when initial imaging is ambiguous, because central diabetes insipidus is often an early sign of pituitary stalk diseases that require longitudinal follow-up.
Finally, suspicion is essential in patients presenting with recurrent dehydration, unexplained hypernatremia, or fluctuations in natremia in relation to changes in fluid intake. In particular, the combination of polyuria and hypernatremia in a patient who cannot drink freely is highly suggestive and requires rapid evaluation for the presence of AVP deficiency, distinguishing it from other causes of high diuresis.
The diagnosis of central diabetes insipidus requires a sequential pathway that first demonstrates the existence of a syndrome of hypotonic polyuria and then confirms its central nature, distinguishing it from nephrogenic diabetes insipidus and primary polydipsia. The first step is to document quantitative polyuria, typically with 24-hour urine collection or serial measurements, and to verify that urine is inappropriately dilute in relation to the patient’s hydration status. In parallel, frequent causes of polyuria must be excluded, such as hyperglycemia, hypercalcemia, renal insufficiency with concentrating defects, and use of medications or substances that increase diuresis.
Baseline laboratory testing should include plasma sodium and plasma osmolality, urinary osmolality and urine specific gravity, together with assessment of renal function. In central diabetes insipidus, urine tends to remain at low osmolality even when plasma osmolality increases, indicating the absence of an adequate antidiuretic response. However, in partial forms and in patients who drink large amounts of water, values may overlap with those of other conditions, making dynamic tests in expert centers necessary.
The classic test is the water deprivation test with assessment of urinary concentrating capacity and response to desmopressin. In a controlled setting, failure to concentrate urine during deprivation and a significant increase in urinary osmolality after desmopressin support a central origin. The test requires close monitoring of weight, diuresis, vital signs, and laboratory parameters, because it exposes the patient to the risk of dehydration and hypernatremia, especially in complete forms. For this reason, patient selection and test management must be rigorous.
In recent years, the use of copeptin, the stable fragment of the AVP precursor, has modified the diagnostic approach. Basal copeptin measurement can identify some forms, but the greatest clinical value derives from stimulation tests, particularly with hypertonic saline infusion or arginine, which increase osmotic or neuroendocrine stimulation and allow more accurate discrimination between central deficiency and other causes of hypotonic polyuria. These tests improve tolerability compared with prolonged water deprivation and reduce diagnostic ambiguity, but they require standardized protocols and monitoring of natremia during stimulation.
Once the central nature of the disorder has been defined, the next phase is identifying the etiology. Magnetic resonance imaging of the hypothalamic-pituitary region is central, since it may show sellar or suprasellar lesions, stalk thickening, abnormalities of the posterior pituitary, and loss of the so-called posterior bright spot. Interpretation must be integrated with the clinical context, because loss of the bright spot is not specific and may be present in different conditions, while stalk thickening requires a structured approach with follow-up and assessment for infiltrative, autoimmune, or neoplastic causes.
It is also necessary to assess anterior pituitary function, because many causes of central diabetes insipidus affect multiple pituitary axes. An unrecognized corticotropic deficiency can be particularly dangerous and, in some cases, treatment with glucocorticoids may unmask polyuria previously masked by reduced glomerular filtration or associated conditions. The final diagnosis is therefore the result of integration between clinical findings, biochemistry, dynamic tests, and imaging, aimed not only at confirming central diabetes insipidus, but also at defining its cause and prognostic implications.
The classification of central diabetes insipidus is clinically relevant because it guides prognosis, risk of complications, and therapeutic strategy. A first classification axis distinguishes complete from partial forms. In complete forms, AVP secretion is severely impaired or absent, with an almost total inability to concentrate urine and a high risk of hypernatremia in the event of reduced water intake. In partial forms, some residual secretion is present, so concentrating capacity is reduced but not abolished; these forms may be more difficult to diagnose and more easily compensated by thirst.
A second axis distinguishes congenital and acquired forms. Congenital forms include familial variants related to preprovasopressin defects and syndromic conditions, often with onset in childhood and possible progression. Acquired forms represent the majority and include neoplastic, postoperative, traumatic, inflammatory, and infiltrative causes. In some cases, the disease remains classified as idiopathic after negative initial investigations, but this category requires caution, because some etiologies only become evident over time.
A third axis concerns transience versus permanence. Central diabetes insipidus may be transient, especially after pituitary surgery or in settings of edema and reversible injury, or permanent when neuronal damage is extensive. Transience does not necessarily coincide with a mild form, because even an initially severe deficiency may lessen if residual fibers recover function or if inflammation resolves.
In postoperative settings, important dynamic patterns exist. The clinical picture may present as a phase of polyuria due to AVP deficiency, followed by a phase of water retention and hyponatremia due to inappropriate AVP release, and a possible subsequent late phase of permanent diabetes insipidus. Understanding this evolution is essential because desmopressin therapy, if not reassessed, may contribute to hyponatremia during the phase of AVP excess, making natremia monitoring a central element of management.
Finally, there is a clinically distinct form, adipsic diabetes insipidus, in which thirst deficiency coexists because of hypothalamic damage. In this condition, clinical severity is defined more by the risk of hyperosmolar dehydration and by the difficulty of self-regulating fluid intake than by the extent of polyuria alone, and it requires scheduled management of water and desmopressin, often with care support and frequent monitoring.
Treatment of central diabetes insipidus aims to safely replace the antidiuretic effect of AVP and prevent complications from water and sodium imbalance, maintaining a balance between control of polyuria and reduction of the risk of iatrogenic hyponatremia. The reference therapy is desmopressin (1-deamino-8-D-arginine vasopressin, dDAVP), a synthetic analogue selective for the V2 receptor, with potent antidiuretic effect and minimal vasopressor activity. The choice of formulation, dose, and frequency must be individualized, considering age, severity of deficiency, comorbidities, lifestyle habits, and risk of errors in fluid management.
Formulations include intranasal, oral, and parenteral administration. Absorption and duration of action vary between routes and between individuals, so adjustment is based mainly on clinical response, urinary volume, thirst, body weight, and periodic sodium checks. In complete forms, the realistic goal is not to abolish diuresis, but to obtain a predictable pattern with windows of free diuresis that reduce the risk of water retention. In partial forms, lower doses or intermittent regimens may be sufficient, with more room for self-regulation of thirst.
A crucial safety principle is patient education to recognize that desmopressin does not correct the cause, but replaces the antidiuretic signal, and that excessive water intake during its action may cause water intoxication and hyponatremia. Practical strategies include adopting a scheduled window without a dose, when clinically feasible, to allow periodic free diuresis, and attention to reducing fluid intake in the presence of symptoms of retention or rapid weight gain. In at-risk patients, more frequent natremia checks are essential, especially during treatment changes, intercurrent illness, or lifestyle changes.
Treatment must also include management of the underlying cause when identifiable. Neoplasms, infiltrative processes, and inflammatory diseases require specific therapies and multidisciplinary follow-up. In some cases, etiological treatment may modify the severity of central diabetes insipidus or lead to partial recovery, making periodic reassessment of desmopressin requirements necessary to avoid overtreatment.
In hospital settings, especially after neurosurgery, treatment must be guided by protocols integrating fluid balance, hourly diuresis, urinary osmolality, and plasma sodium. Desmopressin administration must be cautious and frequently reassessed, since evolution may be rapid and transition to a phase of water retention may occur. In patients with reduced or absent thirst, therapy requires a written plan for fluid intake and desmopressin with targets for weight and sodium, because behavioral self-regulation is inadequate.
Finally, special situations include pregnancy, in which increased AVP catabolism due to placental vasopressinase and changes in the osmotic threshold may coexist, requiring dose reassessment and monitoring. Perioperative management and management during acute illnesses with vomiting or reduced intake also require adjustments, since the risk of dehydration or hyponatremia may change substantially within a few hours.
Follow-up of central diabetes insipidus must ensure stability of natremia, control of symptoms, and surveillance of underlying causes, with particular attention to conditions that may evolve over time. Clinical monitoring includes assessment of thirst, nocturia, urinary volume, sleep quality, body weight, and adherence to therapy. Weight is a practical indicator of fluid balance, because rapid changes may signal retention or water loss before specific symptoms appear.
From a biochemical perspective, periodic measurement of plasma sodium is fundamental, especially in the initial phases of treatment, after changes in dose or formulation, and in the presence of conditions that modify fluid intake. The goal is to prevent both hypernatremia from undertreatment or reduced intake and hyponatremia from excessive desmopressin and water ingestion. In patients with adipsic forms or reduced ability to manage treatment independently, the frequency of monitoring must be greater and it is often useful to integrate management with scheduled intake schemes and family support.
An essential aspect is monitoring of anterior pituitary function, since many etiologies that cause central diabetes insipidus may produce multiple deficiencies over time. Periodic reassessment of the corticotropic, thyrotropic, and gonadotropic axes is important, as is assessment of growth and development in children. Introduction or modification of replacement therapies for other axes may change diuresis and make adjustment of desmopressin necessary.
Radiological surveillance with magnetic resonance imaging is indicated when the etiology is undefined or when findings such as stalk thickening or suspicious abnormalities are present. In cases classified as idiopathic, imaging follow-up over time is crucial because some causes, especially infiltrative or neoplastic ones, may appear late. In pediatrics and young people, this principle is particularly relevant, given that some conditions have a diagnostic window in which early identification modifies prognosis and treatment.
Follow-up must also include continuous education on dose management, warning signs, and behavior in the event of intercurrent illness. The patient should understand when to suspect dehydration, when to reduce fluid intake to avoid hyponatremia, and when to seek urgent evaluation. In working and social life, dose planning to control nocturia and ensure adequate sleep is a realistic goal, but it must always be balanced with electrolyte safety.
The prognosis of central diabetes insipidus depends mainly on the etiology and the quality of therapeutic management. In many patients, well-calibrated desmopressin therapy allows a functionally normal life, with control of polyuria and thirst and reduced impact on sleep quality and daily activities. However, the overall prognosis may be conditioned by the causal disease, particularly in neoplasms and infiltrative disorders, in which central diabetes insipidus is a marker of more extensive hypothalamic-neurohypophyseal involvement.
The most feared complications in the acute phase are related to hyperosmolar dehydration and hypernatremia, which may develop rapidly when water intake is inadequate. Acute or rapidly progressive hypernatremia may cause neurological impairment, seizures, and coma, while slower increases may present with subtle symptoms but still be associated with the risk of thrombotic events, rhabdomyolysis, and prerenal kidney injury if dehydration is significant. The risk is particularly high in hospitalized patients, postoperative patients, and subjects with reduced consciousness or adipsia.
A frequent and often underestimated complication is iatrogenic hyponatremia from desmopressin. Since desmopressin blocks free water excretion, excessive fluid intake during its action may cause retention and reduced sodium, with manifestations ranging from headache and nausea to seizures in severe cases. This risk increases when therapy is intensified to reduce nocturia without providing windows of free diuresis, or when the patient maintains habits of high water intake developed before diagnosis.
In some settings, especially after pituitary surgery, prognosis is complicated by the biphasic or triphasic course of water regulation. In these cases, therapy must be reassessed frequently to prevent fluctuations in natremia. In addition, central diabetes insipidus may coexist with deficiencies of other pituitary axes and with abnormalities of thirst, making the risk of complications higher and control more demanding.
In the long term, the main complication is not direct damage from polyuria, but rather the impact on quality of life, sleep, and the risk of management errors. In well-educated and properly followed patients, the risk of severe events is significantly reduced. Functional prognosis is therefore favorable in most cases, but it requires a specialist approach, appropriate monitoring, and a therapeutic strategy that prioritizes safety and electrolyte stability in addition to symptom control.